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Abstract
Burkholderia pseudomallei is a soil-dwelling bacterium and the causative agent of melioidosis. Isolation of B. pseudomallei
from clinical samples is the ‘‘gold standard’’ for the diagnosis of melioidosis; results can take 3–7 days to produce.
Alternatively, antibody-based tests have low specificity due to a high percentage of seropositive individuals in endemic
areas. There is a clear need to develop a rapid point-of-care antigen detection assay for the diagnosis of melioidosis.
Previously, we employed In vivo Microbial Antigen Discovery (InMAD) to identify potential B. pseudomallei diagnostic
biomarkers. The B. pseudomallei capsular polysaccharide (CPS) and numerous protein antigens were identified as potential
candidates. Here, we describe the development of a diagnostic immunoassay based on the detection of CPS. Following
production of a CPS-specific monoclonal antibody (mAb), an antigen-capture immunoassay was developed to determine
the concentration of CPS within a panel of melioidosis patient serum and urine samples. The same mAb was used to
produce a prototype Active Melioidosis Detect Lateral Flow Immunoassay (AMD LFI); the limit of detection of the LFI for CPS
is comparable to the antigen-capture immunoassay (,0.2 ng/ml). The analytical reactivity (inclusivity) of the AMD LFI was
98.7% (76/77) when tested against a large panel of B. pseudomallei isolates. Analytical specificity (cross-reactivity) testing
determined that 97.2% of B. pseudomallei near neighbor species (35/36) were not reactive. The non-reactive B. pseudomallei
strain and the reactive near neighbor strain can be explained through genetic sequence analysis. Importantly, we show the
AMD LFI is capable of detecting CPS in a variety of patient samples. The LFI is currently being evaluated in Thailand and
Australia; the focus is to optimize and validate testing procedures on melioidosis patient samples prior to initiation of a
large, multisite pre-clinical evaluation.
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Introduction
Burkholderia pseudomallei is an environmental Gram-negative
bacillus and the cause of melioidosis. The clinical manifestations
of melioidosis are broad and include disseminated disease with
organ abscesses, severe sepsis, and mild infection of the skin
and soft tissue [1]. Most patients have risk factors for infection,
which include diabetes, heavy alcohol use, and chronic pulmonary
or kidney disease [1–3]. The highest number of reported cases
occurs in endemic regions of Thailand and Australia. Rising
incidence rates have been recorded in northeast Thailand between
1997–2006, during which the average mortality rate was 42.6%
[3]. In 2006, melioidosis and tuberculosis mortality rates in
northeast Thailand were equivalent and second only to HIV/
AIDS for infectious disease deaths [3]. In northern Australia the
mortality rate over the last five years of the Darwin prospective
melioidosis study was calculated at 9% [2]. The authors attributed
the low mortality rate to early diagnosis and treatment, and access
to and improvements in intensive care management [2].
Isolation of B. pseudomallei from clinical samples remains the
‘‘gold standard’’ against which other melioidosis diagnostics are
compared [4]. Culture is routinely performed on multiple
PLOS Neglected Tropical Diseases | www.plosntds.org 1 March 2014 | Volume 8 | Issue 3 | e2727
sample types (blood, urine, pus, sputum, etc.) and isolation of
B. pseudomallei from any one of these cultures is diagnostic for
melioidosis [5,6]. However, recent modeling data has confirmed
that culturing is an imperfect gold standard [7]. Furthermore,
laboratory processing of positive samples takes 3–7 days [8]. This
problem is compounded by the fact that many diagnostic
laboratories may misidentify B. pseudomallei through lack of
experience or validated diagnostic reagents [9]. Any delay in
diagnostic confirmation is potentially important as B. pseudomallei
requires therapy with ceftazidime or a carbapenem drug, which
are not agents of choice for empirical therapeutic regimens. Taken
together, these factors point to a clear need for a simple and rapid
diagnostic test for accurate identification of B. pseudomallei directly
on clinical samples or cultures.
Prior to diagnostic test development we identified a number of
potential B. pseudomallei diagnostic biomarkers by In vivo Microbial
Antigen Discovery (InMAD) [10,11] that are shed or secreted and
may be targeted to diagnose acute disease. Capsular polysaccha-
ride (CPS) proved to be the most encouraging target; this molecule
is a polymer of 1,3-linked 2-O-acetyl-6-deoxy-b-D-manno-heptopyr-
anose residues [12]. We confirmed CPS was present in melioidosis
patient serum and urine samples by antigen-capture ELISA
utilizing a CPS-specific monoclonal antibody (mAb 3C5) [10].
The current report describes the characterization of mAb 3C5,
quantification of CPS within patient samples, and optimization of
the Active Melioidosis Detect lateral flow immunoassay (AMD
LFI) for the rapid diagnosis of melioidosis.
Materials and Methods
Bacterial cultures
Bacterial isolates listed in Table 1 were cultured on trypticase
soy agar containing 5% sheep blood. Escherichia coli and
B. pseudomallei (strain Bp82) were cultured on Luria Bertani agar
and brain heart infusion agar, respectively. Plates were incubated
at 37uC for 18–24 h. All work with viable B. pseudomallei and
Burkholderia mallei strains was conducted under BSL-3 containment.
All other strains were grown under BSL-2 containment.
Ethics section
Clinical samples from patients with culture-positive melioidosis
were obtained from sample archives (no identifiable private
information supplied) at Mahidol-Oxford Tropical Medicine
Research Unit, Mahidol University, Bangkok, Thailand and
Menzies School of Health Research and Northern Territory
Clinical School, Royal Darwin Hospital, Darwin, Northern
Territory, Australia. Archived and de-identified melioidosis
negative serum and urine samples were obtained from the
University of Nevada School of Medicine, Reno, NV, USA.
Quantitation of B. pseudomallei in urine samples
B. pseudomallei was quantified in urine as previously described
[6]. Briefly, 1 ml of urine was plated on Ashdown agar plates and
incubated overnight at 37uC [13]. Colonies were counted and
expressed as colony forming units (CFU)/ml (Table 1). The
remaining urine was centrifuged at 3000 rpm for 5 min. The
pellet was then plated on an Ashdown agar plate and incubated
overnight. The lower limit of detection was 1 CFU/ml (1 colony
from 1 ml) and the upper limit of detection was $106 CFU/ml
($1000 colonies/1 ml). A positive B. pseudomallei liquid culture
from urine samples that did not show growth on Ashdown agar
plates was estimated to contain ,103 CFU/ml.
Monoclonal antibody affinity determination
Antibody-antigen binding experiments were performed using
surface plasmon resonance (SPR) with a BIAcore X100 instrument
(GE Healthcare, Piscataway, NJ). In each experiment, the running
buffer and sample diluent was 1X HBS-EP+ (GE Healthcare):
10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.05%
surfactant P20, pH 7.4. Biotinylated CPS was immobilized onto
the surface of a streptavidin (SA) sensor chip (GE Healthcare) until
1000 response units (RU) were reached. Purification of CPS has
been previously described [10]. A BIAcore flow cell was left
unmodified for reference subtraction. To evaluate binding affinity,
a two-fold serial dilution of mAb 3C5 (333–5.2 nM) was prepared
in HBS-EP+. Each concentration of mAb was injected over the
sensor surface at flow rate of 30 ml/min for 60 s, after which mAb
was allowed to passively dissociate for 120 s. The sensor surface
was regenerated between runs with a 60 s pulse of 4 M MgCl2 to
ensure the removal of residually bound mAb. The dissociation
constant (KD) was determined using the steady-state model in
BIAevaluation software (GE Healthcare).
Quantitative antigen-capture ELISA
Detection of CPS by antigen-capture ELISA has been described
previously [10]. Briefly, mAb 3C5 (0.25–4 mg/ml) diluted in PBS
was incubated overnight at room temperature in 96-well
microtiter plates (Immulon 1B, Thermo Scientific). The wells
were then washed with PBS-Tween (PBS containing 0.5% Tween
20), and blocked for 90 min in the same solution. Purified CPS in
PBS was serially diluted across the 96-well plate from 100–
0.006 ng/ml, which was used to generate a standard curve to
quantify CPS present in melioidosis patient samples. Wells were
washed with PBS-Tween followed by incubation with HRP-
labeled mAb 3C5 (2 mg/ml) for 90 min. The wells were then
washed and incubated with tetramethylbenzidine substrate
(Kirkegaard & Perry Laboratories) for 30 min. Stop solution
(1 M H3PO4) was then added to the wells and the absorbance was
read at 450 nm. Patient samples were analyzed by a similar
protocol with some minor modifications. Microtiter wells were
coated with 2 mg/ml mAb 3C5. Melioidosis patient serum (1:2
starting dilution) or urine (no starting dilution) was then serially
diluted across the microtiter plate. The CPS concentration in
urine samples was calculated by applying a linear regression to the
plot of log optical density at 450 nm versus log urine dilution with
background correction as described by Peterman [14]. An end
point optical density of 2-fold over background was used for the
calculation of CPS concentrations, using purified CPS as a
standard.
Construction of the AMD LFI
Lateral flow immunoassays were developed using mAb 3C5
targeting the CPS of B. pseudomallei. For the test line, 3C5 was
Author Summary
Burkholderia pseudomallei is an environmental bacterium
and the cause of melioidosis. Culture of patient samples is
the ‘‘gold standard’’ diagnostic test, but may take up to 7
days to complete. Melioidosis has a 10–40% case fatality
rate depending on the geographic location. Delays in
diagnosis could lead to administration of ineffective
antimicrobial therapy, since B. pseudomallei is resistant to
empiric antibiotic regimens. Therefore, we have developed
a lateral flow immunoassay that can be used in the clinical
setting to diagnose melioidosis in 15 minutes. The test
promises to provide improved management of patients
with melioidosis.
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Table 1. Active Melioidosis Detect analytical reactivity and specificity.
Bacterial isolate Strain name/DASH # Lateral Flow Result
Burkholderia pseudomallei 7641; PHLS24; CDC2721620 Positive (+)
Burkholderia pseudomallei Bp25; CDC2721628; 770429 Positive (+)
Burkholderia pseudomallei CDC2721639; PHLS 66 Positive (+)
Burkholderia pseudomallei K96243; NR 9320; CDC0022138 Positive (+)
Burkholderia pseudomallei Bp92; CDC2721623 Positive (+)
Burkholderia pseudomallei Thai 2 NE Human 88; PHLS 45 Positive (+)
Burkholderia pseudomallei Bp104; CDC2721624 Positive (+)
Burkholderia pseudomallei CDC2721635; PHLS 36 Positive (+)
Burkholderia pseudomallei Bp73; Ln31348 Positive (+)
Burkholderia pseudomallei PHLS 208 Positive (+)
Burkholderia pseudomallei CDC2721102; F5013 Positive (+)
Burkholderia pseudomallei BpG9709; CDC0032026 Positive (+)
Burkholderia pseudomallei Sing Env 91; PHLS 19; CDC2721625 Positive (+)
Burkholderia pseudomallei ATCC 23343; CDC2721676; NCTC 12939 Positive (+)
Burkholderia pseudomallei Bp2889; SID2889 Positive (+)
Burkholderia pseudomallei France Env 76; PHLS 33; CDC2721630; 7605 Positive (+)
Burkholderia pseudomallei Bp68; CDC2721641 Positive (+)
Burkholderia pseudomallei Indo 1 Monkey 90; PHLS 17; CDC2721619 Positive (+)
Burkholderia pseudomallei Sing3 Human 88; PHLS 38; S6 Positive (+)
Burkholderia pseudomallei 1106a; U1106a; CDC0022030 Positive (+)
Burkholderia pseudomallei Bp53; CDC2721633; 307a Positive (+)
Burkholderia pseudomallei Bp24; CDC2721620 Positive (+)
Burkholderia pseudomallei BpG9313; CDC0032029 Positive (+)
Burkholderia pseudomallei CDC2721162; B7210; B6195; 904-1111 Positive (+)
Burkholderia pseudomallei CDC2721114; G6715 Positive (+)
Burkholderia pseudomallei Thai NE Env 90; PHLS 216; CDC2721626 Positive (+)
Burkholderia pseudomallei Bp H1406B; CDC0032028 Positive (+)
Burkholderia pseudomallei F1394; 2002721096; 81A442 Positive (+)
Burkholderia pseudomallei CDC2721123; H0929; 98-33; CDC0032024 Positive (+)
Burkholderia pseudomallei Thai NE Human 99; PHLS 392 Positive (+)
Burkholderia pseudomallei CDC1029240; H2001; 2001T-0229 Positive (+)
Burkholderia pseudomallei CDC2721617; PHLS 5; NCTC 8016 Positive (+)
Burkholderia pseudomallei Bp 14; CDC2721618 Positive (+)
Burkholderia pseudomallei Bp H1442; CDC0032025 Positive (+)
Burkholderia pseudomallei MSHR640; CDC8724880 Positive (+)
Burkholderia pseudomallei Australian NT Human 1 97; 465a; CDC8724601 Positive (+)
Burkholderia pseudomallei MSHR99; CDC8724881 Positive (+)
Burkholderia pseudomallei MSHR362; CDC1756207 Positive (+)
Burkholderia pseudomallei MSHR503; CDC8724890 Positive (+)
Burkholderia pseudomallei #711; CDC2721675 Positive (+)
Burkholderia pseudomallei PM19; CDC2734678; 620 Positive (+)
Burkholderia pseudomallei MSHR296; CDC8724908 Positive (+)
Burkholderia pseudomallei MSHR1200; CDC8724883 Positive (+)
Burkholderia pseudomallei CDC2734694; PM40 Positive (+)
Burkholderia pseudomallei PM26; CDC2734683 Positive (+)
Burkholderia pseudomallei Malaysia5 Human; PHLS 75 Positive (+)
Burkholderia pseudomallei MSHR1300; CDC8724901 Positive (+)
Burkholderia pseudomallei PM115; CDC2734709 Positive (+)
Burkholderia pseudomallei STW 424-1; CDC2721825 Positive (+)
Burkholderia pseudomallei Bp40 Positive (+)
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Table 1. Cont.
Bacterial isolate Strain name/DASH # Lateral Flow Result
Burkholderia pseudomallei MSHR365; CDC8724894 Positive (+)
Burkholderia pseudomallei PM138; CDC2734661; SA923 Positive (+)
Burkholderia pseudomallei Malaysia4 Human; PHLS 79 Positive (+)
Burkholderia pseudomallei BpH1689; CDC0032024 Positive (+)
Burkholderia pseudomallei CDC2721184 Positive (+)
Burkholderia pseudomallei CDC2721634 Positive (+)
Burkholderia pseudomallei CDC1756205 Positive (+)
Burkholderia pseudomallei CDC8724905 Positive (+)
Burkholderia pseudomallei CDC0022203 Positive (+)
Burkholderia pseudomallei CDC2721637 Positive (+)
Burkholderia pseudomallei CDC8724896; 1026b Positive (+)
Burkholderia pseudomallei CDC8724889 Positive (+)
Burkholderia pseudomallei CDC8724898 Positive (+)
Burkholderia pseudomallei MSHR1655; 2002721686 (wcbR mutation) Negative (2)
Burkholderia pseudomallei CDC8724899 Positive (+)
Burkholderia pseudomallei CDC8724882 Positive (+)
Burkholderia pseudomallei CDC8724900 Positive (+)
Burkholderia pseudomallei CDC8724892 Positive (+)
Burkholderia pseudomallei CDC8724893 Positive (+)
Burkholderia pseudomallei CDC2721761 Positive (+)
Burkholderia pseudomallei CDC8724885 Positive (+)
Burkholderia pseudomallei CDC0022358 Positive (+)
Burkholderia pseudomallei CDC8724877 Positive (+)
Burkholderia pseudomallei CDC1756206 Positive (+)
Burkholderia pseudomallei CDC8724895 Positive (+)
Burkholderia pseudomallei CDC8724903 Positive (+)
Burkholderia pseudomallei CDC8724878 Positive (+)
Burkholderia mallei KC 238; Kweiyang #4; CDC2721277 Positive (+)
Burkholderia mallei Kweiyang #1; CDC2734821 Positive (+)
Burkholderia mallei KC1090; A188 Pasteur Institute; CDC2721278 Positive (+)
Burkholderia mallei India 65-603; CDC0031066 Positive (+)
Burkholderia mallei NCTC 10247; CDC2734315; Turkey 12 Positive (+)
Burkholderia mallei Turkey 1; CDC0031065 Positive (+)
Burkholderia mallei Turkey 5; CDC2734302 Positive (+)
Burkholderia mallei NCTC 10260; CDC2734314; CDC2734301; Turkey 11; GB6; CCUG 19395 Positive (+)
Burkholderia mallei Rob-DASH (2000031281); CDC0031304 Positive (+)
Burkholderia mallei KC 234; 3873; China 7; CDC2721273 Positive (+)
Burkholderia mallei KC 235; 3873-18; CDC2721274 Positive (+)
Burkholderia mallei KC0248; CDC4017733 Positive (+)
Burkholderia mallei KC 1091; A193 Pasteur Institute; CDC2721279 Positive (+)
Burkholderia mallei KC 1092; CDC2721280; 52-236 Pasteur Institute Positive (+)
Burkholderia mallei BURK011; CDC8724847; C2006251001 Positive (+)
Burkholderia mallei GB9; CDC2734305; Strain 102; NCTC3708 Positive (+)
Burkholderia mallei NCTC 3709 (Strain 106); CDC2724303; GB10 Positive (+)
Burkholderia mallei Turkey 2; BURK063; CDC8724837 Positive (+)
Burkholderia mallei Turkey 3; BURK064; CDC8724838 Positive (+)
Burkholderia mallei Turkey 4; BURK065; CDC8724839 Positive (+)
Burkholderia mallei Turkey 7; BURK068; CDC8724841 Positive (+)
Burkholderia mallei CDC2734300; NCTC10247 Positive (+)
Burkholderia mallei CDC2734301, NCTC10260 Positive (+)
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Table 1. Cont.
Bacterial isolate Strain name/DASH # Lateral Flow Result
Burkholderia mallei CDC2734317; NCTC3709 Positive (+)
Burkholderia mallei CDC2721275 Negative (2)
Burkholderia mallei CDC2734299 Positive (+)
Burkholderia mallei CDC2734311 Negative (2)
Burkholderia mallei CDC0031063 Positive (+)
Burkholderia mallei CDC0031064 Positive (+)
Burkholderia mallei CDC2721276 Positive (+)
Burkholderia mallei CDC2721648 Positive (+)
Burkholderia mallei CDC2734312 Positive (+)
Burkholderia mallei CDC2721280 Negative (2)
Burkholderia thailandensis CDC3015869 (contains capsule operon) Positive (+)
Burkholderia thailandensis CDC2721621 Negative (2)
Burkholderia thailandensis CDC2721627 Negative (2)
Burkholderia thailandensis CDC2721121 Negative (2)
Burkholderia thailandensis CDC2721643 Negative (2)
Burkholderia thailandensis CDC2721701 Negative (2)
Burkholderia thailandensis CDC2721723 Negative (2)
Burkholderia thailandensis CDC2721744 Negative (2)
Burkholderia humptydooensis CDC2721687 Negative (2)
Burkholderia oklahomensis CDC4002358 Negative (2)
Burkholderia oklahomensis CDC4021865 Negative (2)
Burkholderia oklahomensis CDC4021866 Negative (2)
Burkholderia vietnamiensis CDC2734483 Negative (2)
Burkholderia pyrrocinia CDC2724646 Negative (2)
Burkholderia caledonica CDC8724197 Negative (2)
Burkholderia caribensis CDC8724200 Negative (2)
Burkholderia ambifaria CDC8724201 Negative (2)
Burkholderia anthina CDC8724199 Negative (2)
Burkholderia cocovenenans CDC2734715 Negative (2)
Burkholderia ferrariae CDC8724209 Negative (2)
Burkholderia hydrophilia CDC2721759 Negative (2)
Burkholderia fungorum CDC8724198 Negative (2)
Burkholderia glathei CDC2734719 Negative (2)
Burkholderia graminis CDC2734716 Negative (2)
Burkholderia hospita CDC8724207 Negative (2)
Burkholderia kururiensis CDC2734717 Negative (2)
Burkholderia nodosa CDC8724205 Negative (2)
Burkholderia phenazinium CDC2734718 Negative (2)
Burkholderia phenoliruptrix CDC8724203 Negative (2)
Burkholderia phymatum CDC8724208 Negative (2)
Burkholderia phytofirmans CDC8724204 Negative (2)
Burkholderia sacchari CDC8724202 Negative (2)
Burkholderia silvatlantica CDC8724206 Negative (2)
Burkholderia rhizoxinica CDC2734772 Negative (2)
Burkholderia endofungorum CDC2734773 Negative (2)
Burkholderia gladioli CDC3027208 Negative (2)
Escherichia coli ATCC 25922 Negative (2)
Pseudomonas aeruginosa* ATCC 27853 Negative (2)
Streptococcus pneumoniae* ATCC 10015 Negative (2)
Klebsiella pneumoniae* ATCC 13883 Negative (2)
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sprayed onto a nitrocellulose membrane strip. For the control line
goat anti-chicken IgY was sprayed on the same membrane. The
conjugate pad contained dried 40 nm gold particles conjugated to
mAb 3C5 as well as a small amount of gold conjugated chicken
IgY (to react with the control line). The conjugate pad was treated
with a borate-based buffer containing a small concentration of
detergent and dried for later gold conjugate application. The
sample application pad was also treated similarly and dried. The
LFI was assembled by combining the sprayed membrane,
conjugate pad, and sample pad on top of an adhesive plastic
backing. Each layer overlaps by no more than 2–3 mm. Samples
were applied to the sample application pad followed by addition of
a chase buffer to facilitate capillary action. Certain samples types
(e.g. sputum, pus or cultures) were pretreated with a lysis buffer
containing low levels of detergents prior to application to the
sample pad. LFIs were read after 15 minutes and determined to be
positive or negative based on the presence or absence of a pink-red
line at the test line in the presence of a positive control line.
Western blot analysis
A previously described Western blot procedure with semi-dry
blotting was used for this study [15]. Briefly, 86106 bacterial cells
were suspended in Laemmli Sample Buffer (Sigma) and boiled for
10 minutes. The samples were run on a 10% SDS gel followed by
semi-dry transfer onto a PVDF membrane. mAb 3C5 was used at
a final concentration of 0.2 mg/ml. Goat anti-mouse IgG-HRP
(Southern Biotech) was used at a 1:10,000 dilution and signal was
detected with a chemiluminescent substrate (Pierce).
Sample preparation and AMD LFI testing
Bacterial colonies were tested for reactivity on the LFI. An
entire single colony was picked with a sterile loop and suspended
in two drops of lysis buffer. The entire bacterial suspension was
pipetted onto the LFI sample pad followed by the addition of three
drops of chase buffer. Three colonies from each bacterial isolate
listed in Table 1 were tested in this manner. Culture-proven
melioidosis clinical samples (archived) were used to optimize
sample preparation. Serum (50 ml) was combined with 150 ml of
chase buffer; this solution was then applied to the LFI sample pad.
Pus (20 ml) was combined with 100 ml of lysis buffer followed by
vortexing. The lysate (20 ml) was then combined with 150 ml of
chase buffer and applied to the sample pad. Urine was prepared
by first centrifuging a maximum of 10 ml at 32006 g for
10 minutes. The supernatant was removed and the pelleted
material was suspended in 50 ml of lysis buffer. The lysate (20 ml)
was combined with 150 ml of chase buffer and applied to the
sample pad. Sputum (50 ml) was combined with 100 ml of lysis
buffer followed by vortexing. If the sputum sample was viscous
then 20 ml was combined with 150 ml of lysis buffer. The lysate
(20 ml) was combined with 150 ml of chase buffer and applied to
the sample pad. Pleural fluid (30 ml) was combined with 100 ml of
lysis buffer. The lysate (30 ml) was combined with 150 ml of chase
buffer and applied to the sample pad. Control serum (50 ml) spiked
with purified CPS (five-fold serial dilution) was combined with
150 ml of chase buffer and applied to the AMD LFI. Control urine
(50 ml) spiked with purified CPS (five-fold serial dilution) was
combined with 150 ml of chase buffer and applied to the AMD
LFI. Each test was allowed to flow for 15 min and a digital image
was taken of each result.
Results
Our previous report described the ability of mAb 3C5 to detect
B. pseudomallei CPS in urine from patients with melioidosis [10].
Although encouraging, further experiments were required before
constructing a point-of-care diagnostic assay to determine (i) the
affinity of mAb 3C5 for CPS, (ii) the limit of detection of mAb 3C5
for CPS by ELISA, and (iii) the concentration range of CPS that
accumulates in melioidosis patient samples.
SPR was used to determine the functional affinity of mAb 3C5
for B. pseudomallei CPS. Functional affinity is often referred to when
describing the collective effects of mAb bivalency and antigen
multivalency on binding (since CPS is composed of repeating
epitopes). The functional affinity was evaluated on a BIAcore
X100 sensor surface coated with immobilized CPS. The binding
activity of mAb 3C5 was examined over a 60 s injection pulse.
Total (resonance units) RU values were recorded following
binding of a series of mAb concentrations (Fig. 1, left panel).
These RU values were analyzed using a steady-state binding
model (Fig. 1, right panel). This led to the calculation of a 50 nM
dissociation constant (KD) of mAb 3C5 for CPS. This is a relatively
high affinity for a mAb specific to a polysaccharide antigen. This
led us to expect that mAb 3C5 would perform well in an antibody-
based detection assay.
An antigen-capture ELISA for CPS [10] was constructed to
determine the limit of detection (LOD) that could be achieved with
mAb 3C5 (Fig. 2). Due to the polyvalent nature of CPS, mAb 3C5
was used for both capture and detection in this assay. A two-fold
serial dilution of mAb 3C5 was incubated in the solid phase of the
96-well microtiter plate vertically across all eight rows. Following a
wash and blocking step, a two-fold serial dilution of purified CPS
was incubated in the wells (horizontally). Captured CPS was
detected with mAb 3C5 labeled with HRP. An optimal LOD of
0.2 ng/ml (2-fold over background) was achieved with a mAb 3C5
coating concentration of 2 mg/ml.
The antigen-capture ELISA was then used to quantify the
amount of CPS within serum and urine samples collected from
patients with culture-confirmed melioidosis in Thailand. Quan-
titative cultures were performed on urine samples prior to testing
and are reported as CFU/ml (Table 2). Blood cultures were also
tested although the CFU/ml was not determined. Each serum
(isolated from blood) and urine sample was passed through a
0.22 mm filter in order to remove intact bacterial cells prior to
shipment. In our previous report [10] we determined the highest
fold dilution of these samples that yielded an ELISA OD450 value
Table 1. Cont.
Bacterial isolate Strain name/DASH # Lateral Flow Result
Staphylococcus aureus* ATCC 25923 Negative (2)
Enterobacter cloacae* ATCC 23355 Negative (2)
Providencia stuartii* ATCC 33672 Negative (2)
*Indicates strains that were tested for reactivity against mAb 3C5 via western blot.
doi:10.1371/journal.pntd.0002727.t001
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$0.5. For the current study we were able to estimate the
concentration of CPS within these samples by comparing the OD
values to a standard curve produced with purified CPS (Table 2).
CPS was detected in 6/10 filtered urine samples at concentra-
tions ranging from 0.78–448 ng/ml. As expected, the concen-
tration of CPS was higher in samples that contained more CFUs/
ml. CPS was detected in all urine samples containing greater than
1.26104 CFU/ml. CPS was detected in 5/10 filtered serum
samples at concentrations ranging from 0.85 to 6.7 ng/ml.
Following successful detection of CPS by ELISA, a prototype
AMD LFI was constructed. A schematic of the components of the
LFI is depicted in Fig. 3A. Initial LFI testing was performed on B.
pseudomallei strain Bp82, a select agent excluded strain [16], and a
strain of E. coli (negative control). Bp82 was not included in Table 1
since the strain was derived from B. pseudomallei strain 1026b,
which is listed in Table 1. For each test, one single colony was
collected with a sterile loop and resuspended in two drops of lysis
buffer. The lysate was pipetted onto the LFI sample pad followed
by addition of three drops of chase buffer. The fluid migrates by
capillary action into the conjugate pad where gold-labeled mAb
3C5 binds to CPS present in the lysate. The gold-labeled mAb
3C5/CPS complex then migrates into the nitrocellulose mem-
brane and is captured at the test line, which is unlabeled mAb 3C5
bound to the membrane. The absorbent or wicking pad allows for
efficient capillary flow of the sample across the test line. The LFI
used to analyze Bp82 showed test line and control line reactivity
(Fig. 3B, top LFI) while the E. coli LFI was reactive only on the
control line (Fig. 3B, bottom LFI). The tests are run for 15 minutes
and results are recorded and imaged. Presence of the LFI control
line ensures the test has run properly.
The LFI was tested for reactivity to B. pseudomallei and B. mallei
in addition to other near neighbor species (Table 2). Strain panels
tested included isolates selected by the Stakeholder Panel on Agent
Detection Assay (SPADA) Burkholderia Working Group. The
SPADA Burkholderia panel was compiled by a number of key
stakeholders from federal agencies and biothreat researchers [17].
B. mallei has recently been shown to produce the identical manno-
heptose capsule as B. pseudomallei [18]; we have previously shown
mAb 3C5 reactivity to B. mallei CPS by Western blot [10]. The
LFI testing was performed at the Centers for Disease Control and
Prevention to evaluate analytical reactivity and specificity on
inclusivity and exclusivity strain panels. Three colonies from each
isolate listed in Table 1 were tested separately on the LFI. Of the
B. pseudomallei isolates tested, 76/77 (98.7%) were positive; 30/33
(90.9%) of the B. mallei isolates were also positive. In addition, 35/
36 (97.2%) of near neighbor species were negative by LFI. Eight
Burkholderia thailandensis isolates were tested, and seven were
negative. Other near neighbor species where also tested, including
Burkholderia humptydooensis sp. nov., Burkholderia oklahomensis and
Burkholderia cepacia complex (Bcc) species, all of which were
negative. In addition, other medically relevant species of bacteria
were negative for reactivity by Western blot (see footnote to
Table 1) to mAb 3C5 (data not shown).
The LOD of the AMD LFI was determined to verify that the
analytical sensitivity of the assay was sufficiently low to be used to
detect CPS in patient samples. Purified CPS was tested on the LFI
to determine the LOD under optimal conditions (Fig. 4). Dilutions
of CPS were prepared in chase buffer and applied to the LFI
sample pad. The LOD was estimated at or slightly below 0.2 ng/
ml. In addition, purified CPS was spiked into control serum
(Fig. 4B) and urine (Fig. 4C). Under these conditions the LOD was
increased slightly when compared to dilution in chase buffer alone,
however a clear reaction was apparent at 0.2 ng/ml.
The ability of the AMD LFI to accept a variety of patient
samples was assessed with a limited number of culture-positive
melioidosis samples in Australia. These samples were also used
to optimize sample preparation for the AMD LFI. The LFI was
designed to accept multiple sample matrices, which is critically
important for the diagnosis of melioidosis. As shown in Fig. 5A
Figure 1. Calculation of mAb 3C5 affinity for CPS. A BIAcore X100 instrument was used to determine the affinity of mAb 3C5 for CPS.
Biotinylated CPS was immobilized on the surface of a streptavidin sensor chip. Samples (two-fold serial dilution of mAb 3C5 [333–5.2 nM]) were
injected over the sensor surface for 60 s, after which the mAb was allowed to passively dissociate for 120 s (left panel). The dissociation constant (KD)
was determined using the steady-state model in BIAevaluation software (right panel).
doi:10.1371/journal.pntd.0002727.g001
Figure 2. Detection of purified CPS by antigen-capture ELISA.
mAb 3C5 was used in the capture phase of the ELISA at the
concentrations listed. Following a wash and blocking step, purified
CPS was serially diluted across the microtiter plate at the concentrations
listed. The wells were then washed and HRP-labeled mAb 3C5 was used
in the indicator phase to detect captured CPS. The ELISA was performed
in triplicate and mean values are plotted.
doi:10.1371/journal.pntd.0002727.g002
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the samples tested included serum, urine, sputum, pus and
pleural fluid collected from culture-confirmed melioidosis
patients (samples were not collected from the same patient) in
Thailand and Australia. Preparation of each sample prior to
application to the sample pad is described in the Methods
section. The melioidosis patient urine samples that were tested
by antigen-capture ELISA (Table 2) were also tested by LFI
(Fig. 5B). The urine samples that were positive by ELISA were
also positive by LFI. Qualitatively, the test line intensity of the
positive urine samples was congruent with their corresponding
ELISA values.
Discussion
A number of assays have been developed to diagnose
melioidosis prior to culture results becoming available. PCR has
been developed but is not in routine practice because it is limited
by low sensitivity, most likely stemming from the low concentra-
tion of B. pseudomallei in blood and the co-purification of PCR
inhibitors with target DNA [19–21]. However, a recently
developed Type III secretion system (TTS-1) real-time PCR assay
has been shown to be superior to previously developed PCR assays
for detection of B. pseudomallei DNA in clinical specimens [21].
When compared to culture the TTS-1 assay had a sensitivity and
specificity of 80% and 100%, respectively. The indirect hemag-
glutination assay (IHA) is a rapid and inexpensive method used to
detect antibodies produced during infection that are specific to
B. pseudomallei. However, a large percentage of healthy individuals
in endemic areas are seropositive [22,23]. This point is under-
scored by the fact that nearly 70% of children in northeast
Thailand are seropositive for B. pseudomallei antigens [24,25].
Consequently, the IHA (or any serological test for melioidosis) has
limited clinical utility in the endemic setting [1,26].
Antigen detection by immunofluorescence assay (IFA) or latex
agglutination is commonly used in endemic areas. IFA is used in
northeast Thailand for rapid diagnosis directly from patient
samples containing high levels of B. pseudomallei (sputum, pus,
urine and respiratory secretions) [27,28] and from blood cultures
[29]. The main drawback of IFA is the requirement for a
fluorescent microscope and the requisite expertise, which is not
feasible in most endemic settings. In addition, although
specificity of the IFA is high, the sensitivity has recently been
determined to range from 45–48% when used directly on
clinical samples [27]. Latex agglutination is an inexpensive
technique that is effective at identifying B. pseudomallei from
Table 2. Quantification of CPS in melioidosis patient serum
and urine (filtered) by antigen-capture ELISA.
Urinea Serum
Sample CFU/mLa
[CPS]
(ng/ml) Sample
Culture
resultb
[CPS]
(ng/ml)
UID1 2.36104 2.7 MSID1 + 5.4
UID2 .16105 448 MSID2 + ,LOD
UID3 7.56104 20 MSID3 + 6.7
UID4 1.26104 0.78 MSID4 + 3.3
UID5 .16105 66 MSID5 + ,LOD
UID6 3.56103 ,LODc MSID6 + 0.85
UID7 .16105 187 MSID7 + ,LOD
UID9 ,16103 ,LOD MSID8 + ,LOD
UID10 ,16103 ,LOD MSID9 + 1.6
UID12 ,16103 ,LOD MSID10 + ,LOD
aSerum and urine were collected from different patients.
bBlood cultures (serum) are reported only as positive or negative.
cCPS concentrations of these samples were below the LOD of the ELISA.
doi:10.1371/journal.pntd.0002727.t002
Figure 3. Prototype Active Melioidosis Detect (AMD) LFI. (A)
Schematic of LFI components. (B) B. pseudomallei strain Bp82 colony
grown on an agar plate was picked and suspended in 2 drops of lysis
buffer. The lysate was added to the sample pad followed by three drops
of LFI chase buffer (top LFI). The LFI was imaged following a 15 min run
time. The same test condition were used with a colony of E. coli (bottom
LFI).
doi:10.1371/journal.pntd.0002727.g003
Figure 4. Determination of the LOD of the AMD LFI. (A) Purified
CPS was diluted in chase buffer at the indicated concentration and
applied to the LFI sample pad. Results were photographed after 15 min.
Purified CPS was also diluted in human control sera (B) and human
control urine (C).
doi:10.1371/journal.pntd.0002727.g004
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cultures of patient samples grown on agar plates or within liquid
broth [30–33]. The agglutination assay is able to detect B.
pseudomallei at concentrations of 1–26106 CFU/ml; this limits its
utility to cultured patient samples or colonies isolated on solid
agar [32,33].
Our LFI is similar in design to those currently used for the
diagnosis of Streptococcus pneumoniae and Legionella pneumophila [34].
The L. pneumophila assay is a first-line test that relies on detection
of antigen produced by the bacterium within patient urine [35].
We anticipate the AMD LFI can also be used as a first-line test
and offer an improvement over the current rapid techniques for
the diagnosis of melioidosis. In addition we believe lateral flow
devices are well suited for resource poor settings in that they are
inexpensive, rapid, sensitive, and stable at room temperature. In
addition, LFIs do not require expensive equipment and they can
accept multiple sample matrices, two characteristics that are
essential for the diagnosis of melioidosis in resource poor
settings.
IgG3 mAb 3C5 possesses many important characteristics that
are necessary for the development of an antigen detection assay.
It has a relatively high affinity for its target antigen and shows
acceptable analytical reactivity and specificity. The high affinity
translates into a lower limit of detection for CPS by ELISA and
LFI. Interestingly, the LFI had a comparable analytical
sensitivity to the ELISA (,0.2 ng/ml) when CPS was diluted
in chase buffer. The analytical sensitivity was slightly lower when
CPS was spiked into control serum and urine. When tested by
LFI, 98.7% of B. pseudomallei isolates were positive while 97.2% of
near neighbor species were negative. Both the false-negative and
false-positive LFI results can be explained through sequencing
analysis. The one isolate that produced a false negative
(MSHR1655) originated from a patient that developed a
persistent asymptomatic B. pseudomallei infection in Australia. A
frameshift mutation was identified within the wcbR gene of this
isolate [36]. A B. pseudomallei strain (K96243) with a wcbR
mutation was recently shown to have greatly reduced CPS
expression [37]. The one B. thailandensis isolate that produced the
false positive had been previously shown to encode the CPS
biosynthetic operon [38,39].
An essential aspect of the current study was the quantification
of CPS within patient samples. This was accomplished by
comparing ELISA values generated from patient samples with a
standard curve generated with known concentrations of purified
CPS. Over half of the filtered serum and urine samples from
melioidosis patients had levels of CPS within the detection range
of the AMD LFI. The LFI detected CPS in 6/10 culture-positive
urine samples from melioidosis patients. We anticipate that if the
urine had not been filtered more of the samples would have been
positive. Patient serum samples were not tested on the LFI due to
insufficient volumes, but half contained concentrations of CPS
(as determined by ELISA) that could be detected by the AMD
LFI. This is encouraging since the mean concentration of
B. pseudomallei in patient blood is ,1 CFU/ml [5,6]. We
anticipate that CPS may be shed from internal abscesses into
the blood; so theoretically, even if the concentration of bacteria in
blood is low, the concentration of CPS may be within the
detectable range of the LFI. CPS could not be detected in filtered
urine samples that contain low levels of bacteria, suggesting that
CPS may not be shed into urine to detectable levels from the
blood.
This study describes the development and optimization of a
prototype LFI for the rapid diagnosis of melioidosis, including
protocols for the preparation of different sample types. This is
essential since the LFI will be used to test at least four different
bodily fluids, bacterial colonies grown on solid agar, and bacterial
liquid cultures from patient samples. We anticipate routine testing
can be performed on all patient sample types, and the clinical
sensitivity of the LFI will be related to the specific sample type
tested. The sample type producing the lowest sensitivity will most
likely be blood; this is related to the low levels of B. pseudomallei
found in this sample type [5,6]. However, we believe when the LFI
is used to test urine, sputum, and pus, high sensitivity will be
achieved due to the increased CFU/ml values in these matrices.
Now that we have developed reliable sample preparation
guidelines we will perform a larger preclinical analysis in the
endemic areas of Thailand and Australia. The preclinical analysis
will compare the performance of the LFI with the TTS-1 real-time
PCR assay, IFA, and culture (the current ‘‘gold standard’’ for
diagnosis of melioidosis). This will allow us to determine clinical
sensitivity and specificity and the diagnostic utility of the assay.
Further studies are underway to isolate additional CPS specific
mAbs that possess higher affinities than 3C5. Incorporation of
such mAbs into the AMD LFI may lead to increased analytical
and clinical sensitivity.
Author Contributions
Conceived and designed the experiments: DPA RLH DER MAH HC BJC
DL ARH. Performed the experiments: DPA DER MAH MJD HC MM
DSS VT GW BD. Analyzed the data: DPA RLH DER MAH HC BJC
MM DSS DL NC SJP ARH BD. Contributed reagents/materials/analysis
tools: RLH DPA BJC DL NC SJP ARH PJB MNB. Wrote the paper: DPA
SJP RLH.
Figure 5. Prototype AMD LFI for detection of B. pseudomallei
CPS in melioidosis patient samples. (A) Preliminary testing of a
variety of archived patient samples from Australia and Thailand. (B)
Detection of CPS in melioidosis patient urine samples (filtered) listed in
Table 2. Urine (50 ml) was combined with 100 ml of chase buffer and
applied to the sample pad. Note that samples that were positive by
antigen-capture immunoassay (Table 2) were also positive by LFI and
the levels of CPS detected between both assays are congruent.
doi:10.1371/journal.pntd.0002727.g005
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